Benign and malignant tumours were induced in the large bowel of rats by the carcinogen 1,2-dimethylhydrazine (DMH). Benign tumours appeared from week 20 onwards and malignant tumours from week 30. 5-Fluorouracil was administered intraperitoneally in maximally tolerated doses from week 26 onwards and failed to influence significantly the development of either benign or malignant tumours. Tumours induced by DMH are a close model of human colorectal cancer and suitable for testing anticancer drugs. Agents with greater activity against colorectal cancer are required.
Introduction
Chemically-induced colorectal cancer (CRC) in rats resembles human CRC both macroscopically and microscopically and behaves in similar fashion (LaMont & O'Gorman 1978 , Pozharisski et al. 1979 , Schmahl 1982 . It causes intestinal obstruction and metastasizes to lymph nodes and other viscera, and is eventually fatal.
We have investigated the effect on chemically-induced CRC of the antimitotic drug 5fluorouracil (5-FU) -the drug most effective in human CRC (Moertel 1978) .. The experiments were designed to test its effect on the tumours as they developed and on the adenoma--earcinoma sequence (Morson & Dawson 1979, pp 615-647) . The following questions were posed: can 5-FU influence (1) the development of benign tumours; (2) the progression of benign tumours to carcinomata; and (3) the appearance of malignant tumours de novo?
Materials and methods Tumours were induced by 1,2-dimethylhydrazine dihydrochloride (DMH) (Sigma Chemical Co, St Louis, USA) which was freshly prepared prior to each injection according to the method of Filipe (1975) . The DMH was dissolved in 0.9% NaCI containing 1.5% NaEDTA and the pH adjusted to 6.5-7.0 with 5% NaOH. Five injections of DMH were administered subcutaneously at fortnightly intervals at a dose of 40 mg/kg body weight, calculated according to, the base of DMH. Week numbers referred to in the text are taken from the beginning of the course of carcinogen.
Animals were all female Sprague-Dawley rats bred at the Clinical Research Centre and housed' in fives in grid-bottomed cages to minimize coprophagia. 5-Fluorouracil was obtained in unlabelled vials; identical vials containing saline, which were only distinguishable by a different code number, were prepared by the hospital pharmacy for administration to control animals. The experiment was thus conducted in a 'double-blind' fashion. 5-Fluorouracil and the control injection were administered intraperitoneally. All animals were weighed weekly and a necropsy was performed at the time of sacrifice or earlier spontaneous death. All lesions were examined by a histopathologist (EMT) and malignancy was confirmed in all cases by another histopathologist (GS). The absolute requirement for the diagnosis of malignancy was histological infiltration and penetration of the muscularis mucosae by neoplastic tissue, as recommended for human CRC (Morson & Dawson 1979, p 609) . 
Results

Determination of carcinogenic effect
Two groups of 25 animals each received a course of carcinogen. The first group of 25 (5 cages of 5 animals) were culled one cage at a time at weeks 14, 21, 26, 31 and 38. Some animals died prior to the planned sacrifice time both from their tumours and from intercurrent infection. . The second group of 25 animals was observed until their tumours produced signs which necessitated sacrifice. The criteria for sacrifice were loss of weight of more than 10 g/week on four successive weeks, greater than 20% loss of total body weight in one week, and clinically apparent ascites, anaemia or cachexia (after Cruse et al. 1978) . These criteria were also applied to the subsequent experiments.
The combined result for these two groups, showing the numbers of benign and malignant tumours in relation to time, is shown in Figure I . Benign tumours appeared from week 20 onwards and malignant tumours from week 30. Both benign and malignant tumours continued to appear at all times throughout the course of the experiment. It was therefore decided that 5-FU would be given from week 26 to week 34. At this time only a small number of benign tumours would be expected to be present, and both benign and malignant tumours would continue to appear throughout the course of treatment.
5-Fluorouracil toxicity
The effect of 5-FU was assessed in normal animals to determine the dose to be given to animals with DMH-induced tumours. The appropriate dose was considered to be sufficient to produce a small loss of weight only. The loss of weight had to be large enough to indicate an effect for 5-FU but not so large that any effect on tumour growth might be due to nutritional interference (Tannenbaum & Silverstone 1957) .
The regimens chosen were based on the recommended human maintenance dose of 5-15 mg/kg body weight/week (Data Sheet Compendium 1981/82). The human doses were converted for use in the rat according to the recommendations of Freireich et al. (1966) .
The effect of various regimens indicated that a total dose of 50 mg/kg fortnightly produced the desired effect on the weight of normal animals.
Chemotherapy of chemically-induced tumours
Eighty-one animals were randomly allocated to four groups: DMH +saline (21); DMH + 5-FU (20); saline + 5-FU (20); saline +saline (20) . Tumours were induced by DMH as stated above. 5-Fluorouracil was commenced at week 26 with an induction dose of 75 mg/kg body weight, which was followed by a total 'Of five doses of 25 mg/kg body weight each, given twice weekly between weeks 30 and 33. Control animals received an injection of an identical quantity of saline. All injections were intraperitoneal. One animal died in the DMH + saline group prior to the commencement of treatment and has been excluded from analyses of tumours. Six animals died in the DMH + 5-FU group during the course of treatment and these have been retained in all analyses. This experiment was conducted in a bacteriologically clean room and the deaths were not due to intercurrent infection. All the animals in group DMH + 5-FU died because of advancing malignancy to which was added the toxic effect of 5-FU. There were no deaths in the saline+5-FU or saline + saline groups. All animals remaining alive were sacrificed at week 36.
The effect of 5-FU on weight was determined by comparing the mean weight of individual groups to the mean weight of all animals in the experiment. Figure 2 shows the result of this comparison for the two groups of animals that received DMH (DMH + saline and DMH + 5-FU). To determine the effect of 5-FU, these two groups have been compared for the six weeks prior to chemotherapy and the six weeks after its commencement. The difference is not statistically significant (P=O.06, t test). A similar comparison for the two groups of animals that did not receive DMH (saline+5-FU and saline-l-saline) shows a larger effect, with P=0.02. The effect of 5-FU was therefore of the intended magnitude.
Dimethylhydrazine produced 18 benign and 14 malignant tumours in the large bowel of the DMH + saline group and 20 benign and 8 malignant tumours in the DMH + 5-FU group. This' difference fails to reach significance for benign lesions (P=O.5), malignant lesions (P=O.2) or for the total number of lesions combined (P=O.4) (all by Wilcoxon's test). 5-Fluorouracil also failed to influence the size of the tumours (Figure 3 ), or their , anatomical distribution. Metastases were found in three animals in the DMH + saline group and one animal to the DMH + 5-FU group. No tumours were found in the groups that did not receive DMH.
Discussion
Human and chemically-induced colorectal cancer are morphologically very similar. The response to chemotherapy of DMH-induced tumours has been studied in two ways: either tumours may be induced de novo, as in this investigation, or tumour lines may be established by 'serial transplantation after carcinogen induction.
De novo induction for each experiment has the advantage of producing a whole spectrum of tumours of differing grades of malignancy and histological characteristics. This pattern is analogous to the heterogeneous nature of colorectal tumours encountered in man. The principal disadvantage is that the long period for tumour-induction has to be repeated and each experiment takes approximately one year. A single experiment tests only one set of conditions for both the carcinogen and the therapy. In addition, tumour-induction varies according to the animals used, and species, sex and age are known to be influential factors (LaMont & O'Gorman 1978) . Despite the long time required for tumour-induction, this model has been used to examine the response of tumours to chemotherapy. Sych et al. (1978) gave 10 mg/kg body weight of DMH for 25 weeks (a lower and more prolonged dose than we have used) and claimed to produce only malignant tumours. They examined the effect of a combination of 5-FU, methotrexate and cyclophosphamide on tumour size and animal survival. The regimen produced considerable toxicity, a decrease of tumour size, and no prolongation of survival. Danzi et al. (1982) gave DMH at a dose of 40 mg/kg body weight weekly for ten weeks and found that a combination of 5-FU and BCNU (1,3-bis(2-chloroethyl)-I-nitrosourea) significantly prolonged the survival of rats with early carcinomata but not with locally advanced or metastatic disease. Neither of these investigations examined the effect of the therapies on the development of benign tumours or on the transformation of benign tumours to malignant. Narisawa et al. (1978 Narisawa et al. ( , 1980a induced CRC by intrarectal administration of the locallyacting carcinogen N-methyl-N-nitrosourea (MNU). Tumour development was significantly prevented by chemotherapy but only when this was also administered locally (intrarectally). The drugs which were effective were 5-FU and the nitrosoureas MeCCNU (I-(2-chlorethyl)-3-(4-methylcyclohexyl)-I-nitrosourea) and ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride). When 5-FU was given intraperitoneally, the effect did not reach statistical significance. These findings are of considerable interest but are not strictly comparable with the present investigation due to the localized mode of action of the agents used.
The alternative approach has been to develop tumour lines from a batch of carcinogeninduced tumours. This technique has many attractions: the duration of each experiment is considerably shortened as no time is required for tumour induction once the lines are established. Consequently this model is suitable for screening programmes and large numbers of drugs may be assessed for activity. The principal objection to this approach is that the tumour lines are highly selected, and Corbett et al. (1977) produced only four tumour lines from 82 implanted tumours. In addition, the tumours have to be implanted subcutaneously and it is uncertain if their behaviour in this site is identical to their behaviour in the large bowel. These reservations may explain why the drug combination which was most effective against the tumour lines, 5-FU and anguidine, failed to fulfil its promise when tested against human CRC (Goodwin et al. 1981 , Murphy et al. 1979 .
In the present study, there was no difference in the number of either benign or malignant tumours after treatment with 5-FU and this indicates a lack of effect on the development of these tumours de novo. Penetration of the muscularis mucosae and infiltration in the submucosa is sometimes seen in polypoid tumours and suggests that in some cases benign polyps do undergo malignant transformation (Figure 4 ). If this transformation had been inhibited by 5-FU there should have been an increase in the number of benign tumours and a compensatory decrease in the number of malignant lesions. This did not occur, and we conclude that 5-FU produced no effect on any of the modes of tumour development in the regimen used.
The most important evidence for the activity of 5-FU in human CRC rests on the production of 'objective remissions' in advanced (measurable) CRC (Moertel 1976 ). The criteria for objective remission relate to diminution in the size of a measurable metastatic lesion. We observed no effect on the size of the experimental tumours. The experimental tumours were all primary tumours and 5-FU is not known to be effective against primary tumours in man, but only against metastases.
In testing 5-FU against early malignancies and benign tumours we have sought an analogy to .the adjuvant treatment of human CRe. Adjuvant therapy has been defined as the 'postsurgical treatment of minimal residual disease' (Jones & Salmon 1979) and is the treatment of a small or microscopic tumour load, as present in our model. The effect of 5-FU in the adjuvant therapy of human CRC is small and only borders on statistical significance (Moertel 1978 , Davis & Kisner 1978 , Gilbert 1982 . To observe such a small effect would have necessitated a large number of animals. 5-Fluorouracil is sometimes dramatically effective in isolated cases of human CRC (Mack man et al. 1970 (Mack man et al. , 1974 . This may have occurred in a small number of individual experimental tumours, but if it did, it was insufficient to affect the overall level of significance.
Chemically-induced CRC appears to resemble human CRC morphologically, but we must await the development of drugs with greater activity in human CRC before we can determine if its therapeutic sensitivity is similar.
